MupirocinAPO-MUPIROCIN
Treatment of nasal colonisation of staphylococcus aureus infection (including MRSA) in Aboriginal and Torres Strait Islander persons.
Decisions on record
- Meeting Jul 2019 Recommended Staphylococcus aureus infection
- Meeting Mar 2009 Recommended Antibiotic ointment no PSD
- Meeting Mar 2007 Deferred Topical antibacterial no PSD
Access path
- TGA registered · APO-MUPIROCIN
TGA label narrower than the PBS population
- Jul 2019Recommended · restricted
vs mupirocin 2% nasal ointment, 3g (Bactroban®)
- PBS listing · Authority Required
From the public summary
5.1 The PBAC recommended the Section 85 Authority Required (STREAMLINED) listing of a new presentation of mupirocin, in the form 2% nasal ointment 5g (Medsurge) as an alternative to the currently listed mupirocin 2% nasal ointment, 3g (Bactroban®) for the treatment of nasal colonisation of staphylococcus aureus infection in Aboriginal and Torres Strait Islander persons.PSD · Jul 2019
5.2 The PBAC noted that the TGA had accepted that bioequivalence had been established between the Medsurge mupirocin nasal ointment, 5g and the Bactroban®, 3g products.PSD · Jul 2019
Cost-effectiveness
Not modelled — minor submission (new pack size of existing drug). Cost-minimisation approach only; no economic evaluation conducted.
Decision context
PopulationAboriginal and Torres Strait Islander persons with nasal colonisation of staphylococcus aureus (including MRSA).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2019 | Recommended · restricted | mupirocin 2% nasal ointment, 3g (Bactroban®) | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricted subsidy to Aboriginal and Torres Strait Islander persons only; TGA label applies to all populations.
Listed in law
PBS listings commencing 1 Nov 2019 were made by these 3 determinations under the National Health Act 1953. A determination covers every listing that commenced that day, so this is the legal instrument in force for the date — not a document naming this medicine. Open it and check.
| Determination | Made | Status | |
|---|---|---|---|
| PB 84 of 2019 | 30 Oct 2019 | Repealed | PDF ↗ |
| PB 84 of 2019 | 30 Oct 2019 | Repealed | PDF ↗ |
| PB 86 of 2019 | 30 Oct 2019 | Repealed | PDF ↗ |